CHICAGO-Before the dawn of immunotherapy, long-term survival was almost a foreign concept in the metastatic lung cancer. Keytruda Were Still.
At the American Society of Clinical Oncology Annual Meeting, the New Jersey drugmaker triggers outcomes that were 23.2% of previously untreated non-small cell lung cancer patients alive at the five-year mark.
That's beyond the figures of the field historically, according to Scot Ebbinghaus, MD, VP of clinical research at Merck Research Laboratories. Keytruda monotherapy, he said.
"It was very uncommon to see five-year survival prior to the current era of treatment," he said, adding that "five-year survival." year survival for lung cancer has been steady, at least since I was in my oncology fellowship, at about 5%. "
RELATED: Merck's Keytruda wins coveted first-line lung cancer nod, cementing rise 'from laggard to leader '
Keytruda was the first in its class of PD-1
On the flip side, it was high-PD-L1 expressers who drove solo Keytruda's survival benefit in a closely watched phase 3 study that has been rolled out at last year's ASCO meeting. They found that the five-year figures were as high as: 29.6% of patients with tumor proportions scores of 50% or greater compared to the five-year benchmark, compared with just 15.7% of patients with PD-L1 levels below 50%.  RELATED: Merck's solo Keytruda wins again, but might just leave room for competition
25% of patients with PD-L1 levels of 50% or higher made the five-year target, compared with 12.6% of those with expression levels between 1% and 49%. 1% were alive after five years.